AI-Powered Robotics & Intelligent Lab Automation Header Image

 





AI-Powered Robotics & Intelligent Lab Automation
Improve Experimentation, Reproducibility, and Laboratory Efficiency
5/19/2027 - May 20, 2027 ALL TIMES EDT
The AI-Powered Robotics & Intelligent Lab Automation track explores how life sciences organizations are connecting robotics, automation, data, and AI to create more intelligent and increasingly autonomous laboratories. Topics include connected and modular labs, robotic orchestration, automated data capture, AI-ready experimentation, integrated DMTA workflows, and closed-loop optimization. Through real-world implementations, attendees will learn how these approaches accelerate experimental cycles, increase throughput and instrument utilization, improve reproducibility and data quality, reduce manual effort, enable more flexible and scalable laboratory operations, and connect computational intelligence with physical experimentation to advance scientific discovery.
Preliminary Agenda

AUTONOMOUS LABS: AGENTIC AI, ROBOTIC ORCHESTRATION, AND CLOSED-LOOP EXPERIMENTATION

From Automated Workflows to Autonomous Labs: Agentic AI for Closed-Loop Experimentation

Photo of Petrina Kamya, PhD, Global Head of AI Platforms and Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada
Petrina Kamya, PhD, Global Head of AI Platforms and Vice President, Insilico Medicine; President, Insilico Medicine Canada , Global Head of AI Platforms, VP , Insilico Medicine, Canada

As laboratory automation evolves beyond isolated robotic workflows, agentic AI is creating opportunities to connect experimental design, execution, analysis, and decision-making into intelligent, adaptive systems. This presentation explores how AI agents can coordinate laboratory instruments, scientific data, and computational models to enable closed-loop experimentation. Drawing on real-world applications in AI-driven drug discovery, the discussion will examine implementation challenges, human oversight, interoperability, and measurable improvements in experimental efficiency and scientific productivity.

DIGITAL LAB TRANSFORMATION: CONNECTING BENCH SCIENCE, INFORMATICS, AND WORKFLOW AUTOMATION

Where the Bench Meets the Build

Sumathi Palaniswamy, Product Owner, Research BI&T, Sample Management, Bristol Myers Squibb Co. , Product Owner, Research BI&T, Sample Management , Bristol Myers Squibb Co

Our most important sample management system isn’t software. It’s the partnership between the Compound Management team that supports bench scientists and the IT team that builds their tools. This session shares how BMS Compound Management and R&D BI&T replaced request-and-wait with co-ownership: weekly prioritization led by the CM site leads, joint hands-on testing, and vendors working alongside us as partners. That partnership gave us the confidence to build in-house, from CASH to inventory caching and cycle-time data products, closing gaps no vendor platform covers. Leave with a practical blueprint for building the partnership and deciding what to build, buy, or extend.

THE FUTURE OF SCIENTIFIC DISCOVERY: HUMAN JUDGMENT AND AI-DRIVEN R&D

When AI Becomes the Scientist's Partner: Human Judgment and the Future of R&D

Photo of Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Santha Ramakrishnan, PhD, Vice President, Head, R&D Data Strategy and Governance, Bayer Pharmaceuticals , VP, Head, R&D Data Strategy and Governance , Bayer Pharmaceuticals
Photo of Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck
Anu Sharma, Senior Principal Scientist/Senior Director, MRL BARDS Epidemiology RWE Capabilities and Analytics, Merck & Co., Inc. , Senior Principal Scientist and Senior Director , MRL BARDS Epidemiology RWE Capabilities and Analytics , Merck

As AI agents evolve from research assistants into active partners in scientific discovery, what becomes the scientist's unique contribution? How can researchers challenge AI-generated conclusions, recognize overlooked opportunities, and preserve scientific judgment? Senior biopharma leaders will explore how human-AI collaboration is transforming R&D decision-making, operating models, workforce capabilities, and accountability, while examining the leadership and organizational strategies needed to harness increasingly autonomous AI systems for scientific innovation and patient impact.

CHANGING THE TRAJECTORY OF DISEASE: FROM PREDICTION TO INTERVENTION

PLENARY KEYNOTE PRESENTATION: Can we Predict Disease before it Happens? Mapping and Redirecting Biological Trajectories

Photo of John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago
John Quackenbush, PhD, Professor of Pediatrics and Human Genetics, University of Chicago; Professor Emeritus of Computational Biology and Bioinformatics, Harvard T.H. Chan School of Public Health , Professor of Pediatrics and Human Genetics , University of Chicago

Biomedical research has generated increasingly large, rich, and multidimensional datasets, yet we still often study disease by dividing people into discrete categories: healthy or diseased, responder or non-responder, case or control. Biology, however, does not operate in static states. Disease develops along a continuum, shaped by changing regulatory programs and influenced by aging, biological sex, genetics, epigenetics, and environmental exposures.

As our data and computational capabilities advance, an important opportunity is emerging: moving beyond cataloging molecular differences to reconstructing how biological systems change over time. Gene regulatory networks, pseudo-time modeling, and change-point analysis can help identify critical regulatory switches that move a biological system from one state to another and reveal drivers of disease that may be missed when we focus only on individual mutations, genes, or biomarkers.

These approaches are beginning to provide insight into why individuals exposed to similar risks can follow very different disease trajectories, why biological sex can influence disease susceptibility and treatment response, and how aging may reshape the path toward chronic disease. Identifying these transition points may also uncover new therapeutic targets and opportunities to intervene before disease becomes firmly established.

The ultimate vision is a predictive theoretical biology: The ability to understand where an individual is biologically, anticipate where that trajectory may lead, and identify opportunities to redirect it. Moving from describing disease after it occurs toward predicting and ultimately altering its course could transform how we approach target discovery, therapeutic development, and precision medicine.

PLENARY KEYNOTE PRESENTATION: From Data to the Individual: Connecting the Pieces to Deliver Precision Medicine

Photo of Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham
Elizabeth Worthey, PhD, Director, Center for Computational Genomics & Data, University of Alabama Birmingham , Director , Ctr for Computational Genomics & Data , Univ Of Alabama Birmingham

Delivering precision medicine requires more than sophisticated technologies or increasingly complex datasets. Understanding individual patients, particularly those with complex diseases and post-infectious syndromes, demands integration of genomic, molecular, clinical, environmental, and longitudinal information. This presentation explores how connecting fragmented expertise, data, and computational capabilities can bridge the gaps between discovery, biological understanding, and clinical action, advancing a more collaborative, integrated approach to individualized diagnosis and treatment.


Register

Conference Tracks

T1: Data Platforms & Storage Infrastructure